ImmunityBio (IBRX) news
Recent news
Fibra Macquarie technical committee says Fibra MTY offer fair
Fibra Macquarie’s technical committee has concluded that the offer from Fibra MTY is fair, marking a key step in the ongoing merger process. The proposed transaction, valued at approximately $6.5 billion, would combine two major real estate investment trusts in Mexico, creating one of the country’s…
AInvest Wire · 8h agoImmunityBio (IBRX) shares dropped 6.94% intraday, reversing a 9.94% surge on Sept. 23.
ImmunityBio (NASDAQ: IBRX) shares fell 6.94% intraday on Sept. 23, reversing a 9.94% surge from the previous day. The decline followed a warning letter from the U.S. Food & Drug Administration (FDA) regarding misleading promotional materials for Anktiva . The FDA cited a television advertisement…
AInvest Wire · Sep 23, 2026ImmunityBio appoints Dr. Jim Yong Kim, former World Bank president and global health leader, as vice chairman
ImmunityBio, a biotechnology company focused on developing innovative immunotherapies, has appointed Dr. Jim Yong Kim as vice chairman. Dr. Kim, a former president of the World Bank and a globally recognized leader in public health, brings extensive experience in global development and…
AInvest Wire · Aug 10, 2026Shares of ImmunityBio down 2% after posting Q2 loss
AInvest Wire · Aug 4, 2026ImmunityBio Q2 revenue USD 51.24 million vs. IBES estimate USD 49.7 million
ImmunityBio, Inc. (NASDAQ: IBRX) reported second-quarter 2026 total revenue of $51.24 million, exceeding the IBES estimate of $49.7 million. This represents a 92% year-over-year increase and a 15% sequential growth from the first quarter of 2026. The company’s net product revenue for the quarter…
AInvest Wire · Aug 4, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.